Northwest Biotherapeutics Inc (NWBO) — 8-K Filings

8-K Filings (14)

• NW BIO Completes Asset Acquisition/Disposition — Apr 7, 2026 Risk: medium
  On April 7, 2026, NORTHWEST BIOTHERAPEUTICS INC filed an 8-K report detailing the completion of an acquisition or disposition of assets. The period of report fo
• 8-K Filing — Nov 20, 2025
• Northwest Biotherapeutics Enters Material Definitive Agreement — Oct 31, 2025 Risk: medium
  On October 27, 2025, Northwest Biotherapeutics, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, incorpor
• Northwest Biotherapeutics Files Material Definitive Agreement — Oct 30, 2025 Risk: medium
  Northwest Biotherapeutics, Inc. reported a material definitive agreement on October 24, 2025. The filing does not disclose specific details of the agreement, th
• Northwest Biotherapeutics Files 8-K: Other Events — Oct 24, 2025 Risk: medium
  On October 23, 2025, Northwest Biotherapeutics, Inc. filed an 8-K report. The filing indicates an 'Other Events' item, suggesting a significant development not
• Northwest Biotherapeutics Files 8-K Report — Oct 14, 2025 Risk: low
  On October 9, 2025, Northwest Biotherapeutics, Inc. filed an 8-K report. The filing pertains to 'Other Events' and was submitted on October 14, 2025. No specifi
• Northwest Biotherapeutics Secures New Loan Agreement — Dec 26, 2024 Risk: medium
  On December 19, 2024, Northwest Biotherapeutics, Inc. entered into a material definitive agreement, specifically a loan agreement. This agreement creates a dire
• Northwest Biotherapeutics Enters Material Definitive Agreement — Nov 1, 2024 Risk: medium
  On October 31, 2024, Northwest Biotherapeutics, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, incorpor
• Northwest Biotherapeutics Files 8-K — Aug 2, 2024 Risk: medium
  Northwest Biotherapeutics, Inc. filed an 8-K on August 2, 2024, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or
• Northwest Biotherapeutics Files 8-K on Shareholder Votes — Jul 3, 2024 Risk: low
  Northwest Biotherapeutics, Inc. filed an 8-K on July 3, 2024, reporting on matters submitted to a vote of security holders as of June 29, 2024. The filing detai
• Northwest Biotherapeutics Files 8-K — Jun 4, 2024 Risk: medium
  On May 31, 2024, Northwest Biotherapeutics, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executiv
• Northwest Biotherapeutics Enters Material Definitive Agreement — May 2, 2024 Risk: medium
  Northwest Biotherapeutics, Inc. entered into a material definitive agreement on April 26, 2024. This agreement constitutes a direct financial obligation or an o
• Northwest Biotherapeutics Announces Director and Executive Changes — Mar 22, 2024 Risk: medium
  Northwest Biotherapeutics, Inc. announced on March 18, 2024, changes in its board of directors and executive compensation. Specifically, the company reported th
• Northwest Biotherapeutics Reports Officer and Director Changes — Mar 14, 2024 Risk: medium
  Northwest Biotherapeutics, Inc. filed an 8-K on March 14, 2024, reporting changes effective March 8, 2024. These changes include the departure of directors or c

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX